BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $4,969,000 | +13.0% | 499,889 | +3.2% | 0.01% | 0.0% |
Q2 2022 | $4,399,000 | -20.0% | 484,477 | -10.6% | 0.01% | +25.0% |
Q1 2022 | $5,500,000 | -32.7% | 541,891 | +10.7% | 0.00% | 0.0% |
Q4 2021 | $8,169,000 | -62.6% | 489,721 | +5.1% | 0.00% | -63.6% |
Q3 2021 | $21,835,000 | -14.7% | 465,876 | +11.0% | 0.01% | -8.3% |
Q2 2021 | $25,597,000 | +32.9% | 419,892 | +34.3% | 0.01% | +9.1% |
Q1 2021 | $19,259,000 | +128.5% | 312,645 | +163.8% | 0.01% | +120.0% |
Q4 2020 | $8,429,000 | +271.5% | 118,532 | +96.0% | 0.01% | +150.0% |
Q3 2020 | $2,269,000 | +1100.5% | 60,469 | +941.0% | 0.00% | – |
Q2 2020 | $189,000 | +142.3% | 5,809 | +115.1% | 0.00% | – |
Q1 2020 | $78,000 | – | 2,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |